<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531152</url>
  </required_header>
  <id_info>
    <org_study_id>TDR13459</org_study_id>
    <secondary_id>U1111-1153-3544</secondary_id>
    <nct_id>NCT02531152</nct_id>
  </id_info>
  <brief_title>28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Randomized, Observer-masked Study of the Safety, Tolerability and Pharmacodynamics of Sequential Ascending 28-Day Repeated Topical Doses of SAR366234 Versus Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess the local and systemic safety and tolerability of ascending repeated topical doses&#xD;
      of SAR366234 monotherapy in patients with open angle glaucoma (OAG) or ocular hypertension&#xD;
      (OHT) as compared to latanoprost.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To assess the pharmacodynamic activity of ascending repeated topical doses of SAR366234 in&#xD;
      patients with OAG or OHT as compared to latanoprost.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration for one patient is up to 11 weeks, including a screening period of&#xD;
      up to 6 weeks run-in (depending on washout requirements), a 4-week treatment period, and a&#xD;
      1-week follow-up period.&#xD;
&#xD;
      The study design is also a parallel cohort study to assess the safety, tolerability, and&#xD;
      pharmacodynamic activity of SAR366234.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events (including local tolerance and ophthalmological examinations)</measure>
    <time_frame>From screening (Day -42) up to approximately Day 39</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of IOP using Goldman applanation tonometry</measure>
    <time_frame>From screening (Day -42) up to approximately Day 39</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Open Angle Glaucoma -Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>SAR366234 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of SAR366234 will be administered 2 drops per eye per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR366234 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A medium dose of SAR366234 will be administered 1 drop per eye per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR366234 (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A medium dose of SAR366234 will be administered 2 drops per eye per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR366234 (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of SAR366234 will be administered 1 drop per eye per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR366234 (Dose 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of SAR366234 will be administered 2 drops per eye per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A dose of Latanoprost will be administered 1 drop per eye per day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <arm_group_label>Latanoprost</arm_group_label>
    <other_name>Xalatan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR366234</intervention_name>
    <arm_group_label>SAR366234 (Dose 1)</arm_group_label>
    <arm_group_label>SAR366234 (Dose 2)</arm_group_label>
    <arm_group_label>SAR366234 (Dose 3)</arm_group_label>
    <arm_group_label>SAR366234 (Dose 4)</arm_group_label>
    <arm_group_label>SAR366234 (Dose 5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male or female patients ≥18 years of age.&#xD;
&#xD;
          -  Patients diagnosed with OAG (including pseudoexfoliation and pigment dispersion&#xD;
             syndromes and patients with a history of narrow angle closure with a patent peripheral&#xD;
             iridotomy) or OHT.&#xD;
&#xD;
          -  Documented intraocular pressure (IOP) fulfilling the eligibility criteria (below) at&#xD;
             both the screening and baseline visits:&#xD;
&#xD;
          -  At the screening visit&#xD;
&#xD;
          -  an IOP ≤21 mmHg in both eyes if currently treated with an IOP-lowering medication or&#xD;
&#xD;
          -  an IOP ≥22 mmHg and &lt;36 mmHg if treatment-naïve or not on IOP lowering medication for&#xD;
             at least 5 weeks.&#xD;
&#xD;
          -  At the baseline visit following washout&#xD;
&#xD;
          -  an IOP ≥22 mmHg and &lt;36 mmHg at about 8:00 am,&#xD;
&#xD;
          -  an IOP &gt;20 mmHg and &lt;36 mmHg at about 12:00 noon, and&#xD;
&#xD;
          -  an IOP &gt;18 mmHg and &lt;36 mmHg at about 4:00 pm.&#xD;
&#xD;
          -  Baseline laboratory parameters within the defined screening threshold for the&#xD;
             Investigator site, unless the Investigator considers and documents an abnormality to&#xD;
             be clinically irrelevant.&#xD;
&#xD;
          -  Having given written informed consent prior to undertaking any study-related&#xD;
             procedure, including stopping their current glaucoma treatment, if any, and engaging&#xD;
             into the corresponding washout procedures.&#xD;
&#xD;
          -  Patients should agree to discontinue any concomitant topical ocular medication(s) and&#xD;
             current IOP-reducing agents.&#xD;
&#xD;
          -  Best corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity score&#xD;
             of +1.0 logMAR (Snellen equivalent 20/200) or better in both eyes at the screening and&#xD;
             baseline visits.&#xD;
&#xD;
          -  Patients on systemic β blockers must be on a stable dose for at least 2 weeks before&#xD;
             screening and should expect to continue the treatment during the study with no&#xD;
             anticipated alteration in the medication dose.&#xD;
&#xD;
          -  Patients should agree to discontinue contact lenses during treatment with the study&#xD;
             medication.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any clinically significant disease or concomitant medication that would interfere with&#xD;
             the study evaluation.&#xD;
&#xD;
          -  Patients with advanced glaucoma at risk of progression during the study in the opinion&#xD;
             of the Investigator.&#xD;
&#xD;
          -  Presence or history of hypersensitivity to latanoprost or known history of&#xD;
             non-response to any prostaglandin analog given for the reduction of IOP.&#xD;
&#xD;
          -  History of hypersensitivity or allergy to any component of the investigational&#xD;
             medicinal product or any of the diagnostic medications or materials used in the&#xD;
             conduct of the study.&#xD;
&#xD;
          -  Use or expected need for ocular (topical, periocular, or intravitreal), local (inhaled&#xD;
             or nasal), or systemic glucocorticoid medications within 4 weeks prior to the baseline&#xD;
             visit and for the duration of the study.&#xD;
&#xD;
          -  Any vaccination within the last 28 days from randomization or during screening&#xD;
             whichever is longer.&#xD;
&#xD;
          -  Any patient in the exclusion period of a previous study according to applicable&#xD;
             regulations.&#xD;
&#xD;
          -  Any patient who cannot be contacted in case of emergency.&#xD;
&#xD;
          -  Any patient who is the Investigator or any subinvestigator, research assistant,&#xD;
             pharmacist, study coordinator, or other staff thereof, directly involved in conducting&#xD;
             the study.&#xD;
&#xD;
          -  Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen,&#xD;
             anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and&#xD;
             2 antibodies (anti-HIV1 and anti HIV2 Ab).&#xD;
&#xD;
          -  Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine, opiates) unless the result of a medical&#xD;
             prescription.&#xD;
&#xD;
          -  An IOP ≥36 mmHg at any time during the screening, baseline, or randomization visits&#xD;
             (Day 1 predose).&#xD;
&#xD;
          -  History of ocular surgery (including laser) or trauma in either eye within 6 months of&#xD;
             the screening visit.&#xD;
&#xD;
          -  History of glaucoma filtering surgery or aqueous shunt procedures (traditional valves&#xD;
             and/or microinvasive glaucoma surgery [MIGs]).&#xD;
&#xD;
          -  History of ocular infection within the past 3 months or ongoing or recurrent ocular&#xD;
             inflammation (ie, moderate to severe blepharitis, allergic conjunctivitis, herpetic&#xD;
             keratitis, peripheral ulcerative keratitis, scleritis, or uveitis) in either eye. Any&#xD;
             ocular abnormalities or symptoms indicative of ongoing ophthalmic disease (except if&#xD;
             related to glaucoma or OHT).&#xD;
&#xD;
          -  Central corneal thickness &lt;500 µm or &gt;620 µm at the baseline visit.&#xD;
&#xD;
          -  Any evidence of cornea guttata or corneal endothelial dysfunction from medical history&#xD;
             or at the baseline visit.&#xD;
&#xD;
          -  Uncontrolled disease that would interfere with the study conduct, the interpretation&#xD;
             of the study results, or the ability of the patient to meet the requirements of the&#xD;
             study schedule.&#xD;
&#xD;
          -  Any corneal abnormalities preventing reliable applanation tonometry.&#xD;
&#xD;
          -  Closed/barely open anterior chamber angle or a history of acute angle closure in&#xD;
             either eye not adequately treated with a peripheral iridectomy.&#xD;
&#xD;
          -  Diagnosis of a clinically significant or progressive retinal disease (eg, diabetic&#xD;
             retinopathy, advanced age-related macular degeneration, inherited retinal dystrophies)&#xD;
             in either eye.&#xD;
&#xD;
          -  Advanced optic nerve abnormality or history of visual field loss in either eye based&#xD;
             on the assessment of the Investigator which could put the patient at risk of glaucoma&#xD;
             progression by participating in the study.&#xD;
&#xD;
          -  History of aphakia, pseudophakia with a torn posterior lens capsule, macular edema, or&#xD;
             known risk factors for macular edema in either eye.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>St Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

